Tiziana Bachetti Selected Research

Alexander Disease (Alexander's Disease)

1/2021	Beneficial Effect of Phenytoin and Carbamazepine on GFAP Gene Expression and Mutant GFAP Folding in a Cellular Model of Alexander's Disease.
12/2020	Alexander Disease Modeling in Zebrafish: An In Vivo System Suitable to Perform Drug Screening.
1/2013	Ceftriaxone for Alexander's Disease: A Four-Year Follow-Up.
9/2012	Beneficial effects of curcumin on GFAP filament organization and down-regulation of GFAP expression in an in vitro model of Alexander disease.
12/2010	Correspondence regarding: Alexander disease mutant glial fibrillary acidic protein compromises glutamate transport in astrocytes.
8/2010	In vitro treatments with ceftriaxone promote elimination of mutant glial fibrillary acidic protein and transcription down-regulation.
3/2010	Ceftriaxone has a therapeutic role in Alexander disease.
4/2008	Mild functional effects of a novel GFAP mutant allele identified in a familial case of adult-onset Alexander disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tiziana Bachetti Research Topics

Disease

12	Congenital central hypoventilation syndrome 01/2022 - 07/2005
8	Alexander Disease (Alexander's Disease) 01/2021 - 04/2008
7	Neuroblastoma 11/2021 - 01/2005
6	Inflammation (Inflammations) 04/2022 - 08/2004
4	Hypoxia (Hypoxemia) 01/2017 - 09/2006
4	Hypercapnia 01/2017 - 09/2006
3	COVID-19 03/2022 - 06/2021
3	Neoplasms (Cancer) 11/2021 - 08/2015
3	Necrosis 06/2013 - 08/2004
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2020 - 12/2007
2	Hirschsprung Disease (Hirschsprung's Disease) 01/2017 - 02/2007
2	autosomal dominant familial Periodic fever 06/2014 - 06/2013
1	Hypertension (High Blood Pressure) 04/2022
1	Vascular Diseases (Vascular Disease) 04/2022
1	Post-Acute COVID-19 Syndrome 03/2022
1	Carcinogenesis 03/2022
1	Fibrosis (Cirrhosis) 06/2021
1	Infections 04/2021
1	Enterocolitis 04/2021
1	Sudden Death 01/2021
1	Seizures (Absence Seizure) 01/2021
1	Chronic Disease (Chronic Diseases) 10/2020
1	Unexplained Event Resolved Brief 01/2020
1	Sudden Infant Death (SID) 01/2020
1	Body Weight (Weight, Body) 01/2018
1	Neoplasm Metastasis (Metastasis) 01/2018
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 01/2018
1	Pathologic Constriction (Stenosis) 06/2017
1	Atherosclerosis 06/2017
1	Myoclonus (Nocturnal Myoclonus) 01/2013
1	Gait Ataxia 01/2013
1	Dysarthria (Spastic Dysarthria) 01/2013
1	Astrocytoma (Pilocytic Astrocytoma) 09/2012
1	Congenital, Hereditary, and Neonatal Diseases and Abnormalities (Congenital Disorders) 09/2011
1	Muscular Dystrophies (Muscular Dystrophy) 09/2011
1	type 2 Syndactyly 09/2011
1	Polymorphic catecholergic ventricular tachycardia 01/2011
1	Ventricular Tachycardia 01/2011
1	Gliosis 11/2010
1	Neurodegenerative Diseases (Neurodegenerative Disease) 08/2010

Drug/Important Bio-Agent (IBA)

11	polyalanineIBA 01/2022 - 07/2005
6	Proteins (Proteins, Gene)FDA Link 04/2021 - 04/2006
5	Glial Fibrillary Acidic ProteinIBA 01/2021 - 04/2008
3	Transcription Factors (Transcription Factor)IBA 11/2021 - 01/2005
3	Pharmaceutical PreparationsIBA 01/2021 - 08/2015
3	Alanine (L-Alanine)FDA Link 01/2017 - 01/2007
3	Ceftriaxone (Ceftriaxon)FDA LinkGeneric 01/2013 - 03/2010
2	Biomarkers (Surrogate Marker)IBA 04/2022 - 01/2018
2	RNA (Ribonucleic Acid)IBA 03/2022 - 01/2020
2	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2022 - 12/2007
2	Biological ProductsIBA 06/2021 - 01/2017
2	CytokinesIBA 06/2021 - 11/2010
2	3' Untranslated Regions (3' UTR)IBA 01/2021 - 02/2007
2	CurcuminIBA 01/2018 - 09/2012
2	Messenger RNA (mRNA)IBA 01/2017 - 09/2006
2	Mutant Proteins (Protein, Mutant)IBA 06/2014 - 06/2013
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 06/2014 - 09/2006
2	Neuroprotective AgentsIBA 09/2012 - 08/2010
2	Protein Isoforms (Isoforms)IBA 05/2005 - 08/2004
1	Angiotensin Receptor AntagonistsIBA 01/2022
1	MicroRNAs (MicroRNA)IBA 11/2021
1	Oncostatin M Receptors (Oncostatin M Receptor)IBA 04/2021
1	Clomipramine (Anafranil)FDA LinkGeneric 01/2021
1	Anticonvulsants (Antiepileptic Drugs)IBA 01/2021
1	Carbamazepine (Tegretol)FDA LinkGeneric 01/2021
1	Phenytoin (Dilantin)FDA LinkGeneric 01/2021
1	SenotherapeuticsIBA 10/2020
1	EnzymesIBA 01/2018
1	Adenosine Triphosphate (ATP)IBA 01/2018
1	NF-kappa B (NF-kB)IBA 01/2018
1	PolyphenolsIBA 01/2018
1	Indicators and Reagents (Reagents)IBA 06/2017
1	vasostatin IIBA 06/2017
1	Chromogranin AIBA 06/2017
1	Peptides (Polypeptides)IBA 06/2017
1	Mycophenolic Acid (Cellcept)FDA LinkGeneric 01/2017
1	Chloroquine (Aralen)FDA LinkGeneric 01/2017
1	Anti-Bacterial Agents (Antibiotics)IBA 06/2013
1	Type I Tumor Necrosis Factor ReceptorsIBA 06/2013
1	Reactive Oxygen Species (Oxygen Radicals)IBA 06/2013
1	InterleukinsIBA 06/2013
1	geldanamycinIBA 06/2013
1	Small Heat-Shock ProteinsIBA 09/2012
1	Green Fluorescent ProteinsIBA 09/2012
1	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 09/2012
1	Calcium-Calmodulin-Dependent Protein KinasesIBA 01/2011
1	CatecholaminesIBA 01/2011
1	KN 93IBA 01/2011
1	Ryanodine Receptor Calcium Release Channel (Ryanodine Receptor)IBA 01/2011
1	Calcium-Calmodulin-Dependent Protein Kinase Type 2IBA 01/2011
1	Adrenergic Agents (Adrenergic Drugs)IBA 01/2011
1	KN 92IBA 01/2011
1	Glutamic Acid (Glutamate)FDA Link 12/2010
1	Hormones (Hormone)IBA 11/2010
1	Transcription Factor AP-1 (Transcription Factor AP 1)IBA 11/2010
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 11/2010
1	UbiquitinIBA 08/2010

Therapy/Procedure

5	Therapeutics 03/2022 - 04/2010
1	Critical Care (Surgical Intensive Care) 03/2022
1	Long-Term Care 03/2022